These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25546165)

  • 1. Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
    Ge J; Ding LK; Yang J; Jia YY; Lu CT; Ding Y; Song Y; Song W; Wen AD
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):272-6. PubMed ID: 25546165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers.
    Quetglas EG; Campanero MA; Sádaba B; Escolar M; Azanza JR
    Arzneimittelforschung; 2008; 58(6):283-7. PubMed ID: 18677970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
    Izquierdo I; Borja J; Rovira S; Pelagio P; Torres F; Cebrecos J; García-Rafanell J
    Arzneimittelforschung; 2010; 60(1):36-41. PubMed ID: 20184225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.
    Ramis J; Mis R; Forn J; Torrent J; Gorina E; Jané F
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):269-73. PubMed ID: 1823870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
    Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
    BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
    Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Yun HY; Baek IH; Kwon KI; Yoon YR
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1471-9. PubMed ID: 22098139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
    Wang M; Zhang Q; Huang M; Zong S; Hua W; Zhou W
    Drug Res (Stuttg); 2014 May; 64(5):263-8. PubMed ID: 24105106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR; Digiacinto J; Davis MW
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of triflusal after single and repeated doses in man.
    Ramis J; Torrent J; Mis R; Conte L; Barbanoj MJ; Jané J; Forn J
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):344-9. PubMed ID: 2272716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
    Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
    Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
    Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.
    Valle M; Barbanoj MJ; Donner A; Izquierdo I; Herranz U; Klein N; Eichler HG; Müller M; Brunner M
    Eur J Clin Pharmacol; 2005 Apr; 61(2):103-11. PubMed ID: 15711832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
    Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
    Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers.
    Johnson FK; Mudd PN; Janmohamed SG
    Clin Pharmacol Drug Dev; 2015; 4(3):193-202. PubMed ID: 27140799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of triflusal and its main metabolite in rats and dogs.
    Ramis J; Mis R; Forn J
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):261-8. PubMed ID: 1823869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.
    Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N
    Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.